Health
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Headline as filed by CNBC Business.
Compare coverage — 1 report
| Publisher | Headline | Summary | Published | Detected | Delay | Source | Status |
|---|---|---|---|---|---|---|---|
| CNBC Business | Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s |
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes. |
0m | cnbc.com | First |
Headlines and summaries belong to the publisher named beside them. “Published” is what their feed stated; “detected” is when PageNews first held the report. Delay is measured from the earliest report on this event and describes timing only.
Reader comments
Comments are written by readers. PageNews does not check them and does not stand behind them, and a name here is a name someone typed, not a person we have identified.
Nobody has commented on this story yet.